Overview

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Status:
Completed
Trial end date:
2020-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Treatments:
Ozanimod